SynthesisAdvanced drug delivery reviews2022
Monocytes as a convergent nanoparticle therapeutic target for cardiovascular diseases.
Synthesis in Advanced drug delivery reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Capturing the dynamics of STAT6 macrophage polarization using bioluminescence temporal signatures.Cell systems · 2026Article
- Impact of systemic immune-inflammation index and systemic inflammation response index on all-cause and cause-specific mortality: a community-based cohort study.Frontiers in medicine · 2026Article
- Rapid and label-free isolation of human peripheral blood monocytes using a reversible CD36-binding aptamer for cell capture.Biomaterials science · 2025Article
- Gold Nanoparticles in Atherosclerosis: A Dual Approach to Diagnosis and Therapy.Molecular imaging and biology · 2025Review
- The value of the monocyte to high-density lipoprotein cholesterol ratio in predicting the thrombosis burden and long-term prognosis of acute myocardial infarction patients: a retrospective cohort study.Journal of thoracic disease · 2025Article
- Covalent modification of iron oxide-poly(lithocholic acid) nanoparticles with folic acid or doxorubicin - an approach for enhanced cancer therapy.RSC advances · 2025Article
- Sequential delivery of cardioactive drugs via microcapped microneedle patches for improved heart function in post myocardial infarction rats.Acta biomaterialia · 2025Article
- Pluronic F127/lecithin PLGA nanoparticles as carriers of monocyte-targeted jakinibs: a potential therapeutic platform.Nanomedicine (London, England) · 2025Article
- Targeted Delivery of Nanoparticles to Blood Vessels for the Treatment of Atherosclerosis.Biomedicines · 2024Review
- Oxidized mRNA Lipid Nanoparticles forAdvanced functional materials · 2024Article
- PLGA-LEC/F127 hybrid nanoparticles loaded with curcumin and their modulatory effect on monocytes.Nanomedicine (London, England) · 2024Article
- scRNA-seq analysis discovered suppression of immunomodulatory dependent inflammatory response in PMBCs exposed to silver nanoparticles.Journal of nanobiotechnology · 2024Article
- Monocyte regulation by gut microbial signals.Trends in microbiology · 2023Review
- Monocytes in neonatal stroke and hypoxic-ischemic encephalopathy: Pathophysiological mechanisms and therapeutic possibilities.Neuroprotection (Chichester, England) · 2023Review
- Harnessing Biomaterials for Immunomodulatory-Driven Tissue Engineering.Regenerative engineering and translational medicine · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Due to the increasing population of individuals with cardiovascular diseases and related comorbidities, there is an increasing need for development of synergistic therapeutics. Monocytes are implicated in a broad spectrum of diseases and can serve as a focal point for therapeutic targeting. This review discusses the role of monocytes in cardiovascular diseases and highlights trends in monocyte targets nanoparticles in three cardiovascular-related diseases: Diabetes, Atherosclerosis, and HIV. Finally, the review offers perspectives on how to develop nanoparticle monocyte targeting strategies that can be beneficial for treating co-morbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.